

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT METRONIDAZOLE AND SODIUM CHLORIDE INJECTION PASSED CONSISTENCY EVALUATION**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for Metronidazole and Sodium Chloride Injection of Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, in which its 250ml:1.25g specification being the first one and its 100ml:0.5g specification being the second one of their respective approvals in the PRC.

Metronidazole is a commonly used antibiotic. It is mainly used for treatment or prevention of systemic or local infections caused by anaerobic bacteria, including anaerobic bacterial infections in the abdominal cavity, digestive tract, female reproductive system and oral cavity.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
Company Secretary

Hong Kong, 12 March 2021

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*